SPOTLIGHT: Merck partners with Addex

Addex Pharmaceuticals' approach to receptor modulation has been validated in a new deal with Merck. The pharma giant will pay $3 million up front, and up to $170.5 million in fees and milestones, in a collaboration to develop new therapies for Parkinson's disease. Switzerland-based Addex has been working on new technology that can modulate a receptor, rather than just turn it on or off. The new approach can fine tune the impact of a drug, which in turn could increase efficacy and decrease side effects. Release

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.